Vol.

No.

December 02, 2022Dec 02, 2022

DOWNLOAD THE PDF

Cover Story

Clinical

FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC

By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg

Pragmatica-Lung is shaping up as the clinical trial to watch—not just because of the research question, but because of the way it’s being addressed.

Conversation with The Cancer Letter

Roy Herbst: I hope Pragmatica-Lung will become the norm

By Jacquelyn Cobb and Paul Goldberg

Conversation with The Cancer Letter

Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex

By Matthew Bin Han Ong

Free Obituary

UNC’s Jo Anne Earp, behavioral scientist and civil rights activist, dies at 79

By Elizabeth French

Free In the Archives

Podcasts, panels, and archives of the first NCI-designated cancer centers

In Brief

Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers

William K. Oh named CMO of the Prostate Cancer Foundation

UPMC Hillman names Geyer, Baskin, Schmitz to leadership posts

Ulrich Steidl named chair of cell biology at Albert Einstein

OSUCCC–James, Ohio State program aims to identify lung cancers early

Melissa D. Fana named director of women’s health at NYU Langone Health, Suffolk County

Clinical Roundup

Keytruda meets primary endpoint of OS in HER2-negative gastric cancer

Adjuvant Keytruda provides higher QoL than standard of care immunotherapy in melanoma

VCU Massey study identifies genetic driver of pancreatic cancer

New approach to managing post-surgery pain reduces opioid-based medication use by 50%

Estrogen-blocking drugs could offer mortality benefit for women with elevated breast cancer risk

Johns Hopkins researchers generate lab-grown human tissue model for gastroesophageal junction cancer

AI-enabled study shows mechanics of aging and disease progression

Multicenter study reveals worse outcomes in understudied breast cancer

Drugs & Targets

FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation

EC approves Libtayo for advanced cervical cancer

Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer

AstraZeneca to acquire Neogene Therapeutics for $320M to develop T cell receptor therapies

NCI Trials

NCI Trials for December 2022

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 07 - February 21, 2025